{"id":"placebo-methotrexate-mtx","safety":{"commonSideEffects":[{"rate":"20–30%","effect":"Nausea and gastrointestinal upset"},{"rate":"5–15%","effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":"5–10%","effect":"Hepatotoxicity"},{"rate":"3–10%","effect":"Mouth ulcers / stomatitis"},{"rate":"2–5%","effect":"Alopecia"},{"rate":"variable","effect":"Infection risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methotrexate is a folate antagonist that blocks dihydrofolate reductase, thereby inhibiting nucleotide synthesis and cell division. In rheumatologic and autoimmune conditions, it suppresses T-cell and B-cell proliferation and reduces production of pro-inflammatory cytokines. The placebo control in this phase 3 trial serves as a comparator to assess MTX efficacy.","oneSentence":"Methotrexate inhibits dihydrofolate reductase to suppress DNA synthesis and reduce inflammatory immune cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:35.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Other autoimmune/inflammatory conditions (specific indication dependent on trial protocol)"}]},"trialDetails":[{"nctId":"NCT07280156","phase":"PHASE2","title":"A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)","status":"RECRUITING","sponsor":"Protalix","startDate":"2025-12-22","conditions":"Gout","enrollment":150},{"nctId":"NCT07176390","phase":"PHASE2","title":"A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Arthritis, Rheumatoid","enrollment":182},{"nctId":"NCT07171983","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-28","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT01143337","phase":"PHASE2","title":"Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2010-06","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT04483466","phase":"PHASE3","title":"Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"George Washington University","startDate":"2023-07-18","conditions":"Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease Severity","enrollment":150},{"nctId":"NCT06590090","phase":"PHASE2","title":"Natrunix in Combination With Methotrexate for Rheumatoid Arthritis Treatment","status":"NOT_YET_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2026-07-15","conditions":"Rheumatoid Arthritis","enrollment":108},{"nctId":"NCT05879419","phase":"PHASE4","title":"Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-05-23","conditions":"Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis","enrollment":2005},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT06671054","phase":"PHASE2","title":"A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2024-10-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":240},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT07161336","phase":"PHASE2","title":"Role of Methotrexate in Ultrasound Proven Synovitis in Primary Knee OA","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2025-07-30","conditions":"Osteo Arthritis of the Knee, Synovitis of Knee, Methotrexate","enrollment":70},{"nctId":"NCT03775460","phase":"NA","title":"Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-01-15","conditions":"Erythema Nodosum Leprosum","enrollment":550},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06281184","phase":"","title":"A 30-month Follow-up of MERINO Participants to Evaluate Long-term Effects of Methotrexate in Erosive Hand OA.","status":"ENROLLING_BY_INVITATION","sponsor":"Diakonhjemmet Hospital","startDate":"2024-07-29","conditions":"Hand Osteoarthritis, Erosive Osteoarthritis","enrollment":108},{"nctId":"NCT06231745","phase":"PHASE3","title":"Paroxetine Safety and Efficacy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2024-01-31","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05374785","phase":"PHASE2","title":"Efficacy and Safety Study Comparing CPL409116 to Placebo in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celon Pharma SA","startDate":"2022-05-01","conditions":"Rheumatoid Arthritis","enrollment":106},{"nctId":"NCT05363891","phase":"PHASE2","title":"Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"XBiotech, Inc.","startDate":"2023-08-08","conditions":"Rheumatoid Arthritis","enrollment":243},{"nctId":"NCT01451203","phase":"PHASE3","title":"Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2011-10-11","conditions":"Rheumatoid Arthritis","enrollment":319},{"nctId":"NCT06724952","phase":"PHASE4","title":"Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Rheumatoid Arthritis (RA)","enrollment":44},{"nctId":"NCT05604885","phase":"PHASE2","title":"A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2022-11-30","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT03257852","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-09-29","conditions":"Rheumatoid Arthritis (RA)","enrollment":66},{"nctId":"NCT02305849","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-07-25","conditions":"Rheumatoid Arthritis","enrollment":519},{"nctId":"NCT02884635","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-09-16","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":"Rheumatoid Arthritis (RA)","enrollment":385},{"nctId":"NCT06641128","phase":"PHASE4","title":"The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2024-10-15","conditions":"Rheumatoid Arthritis (RA), Methotrexate Induced Nephrotoxicity, Methotrexate Adverse Reaction","enrollment":44},{"nctId":"NCT03016013","phase":"PHASE3","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2017-03-29","conditions":"Moderate and Severe RheumatoId Arthritis","enrollment":479},{"nctId":"NCT04170504","phase":"PHASE2, PHASE3","title":"Efficacy of Chinese Herbal Medicine Qing Re Huo Xue in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2019-11-14","conditions":"Rheumatoid Arthritis","enrollment":204},{"nctId":"NCT05279417","phase":"PHASE2","title":"ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2022-02-01","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT05594680","phase":"PHASE3","title":"Cilostazol and Methotrexate in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-10-01","conditions":"Rheumatoid Arthritis","enrollment":70},{"nctId":"NCT03980483","phase":"PHASE3","title":"Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-05-16","conditions":"Arthritis, Rheumatoid","enrollment":1537},{"nctId":"NCT01751776","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-12-18","conditions":"Arthritis, Rheumatoid, Healthy","enrollment":107},{"nctId":"NCT03815448","phase":"NA","title":"Methotrexate in the Treatment of Advanced Knee Osteoarthritis With Effusion-synovitis","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2019-07-18","conditions":"Knee Osteoarthritis, Effusion Synovial, Knee Pain","enrollment":215},{"nctId":"NCT02706951","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03-23","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT02663622","phase":"PHASE2","title":"Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)","status":"COMPLETED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2016-09-19","conditions":"Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia","enrollment":44},{"nctId":"NCT03371667","phase":"PHASE3","title":"To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-08-16","conditions":"Allogeneic Disease, GVH - Graft Versus Host Reaction, GVHD, Acute","enrollment":102},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT00579878","phase":"PHASE3","title":"Triple III Comparison of Leflunomide Alone Versus Two DMARD Combinations in the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2001-03-27","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT02706873","phase":"PHASE3","title":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-23","conditions":"Rheumatoid Arthritis","enrollment":1002},{"nctId":"NCT02270632","phase":"PHASE2","title":"A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX","status":"TERMINATED","sponsor":"Philogen S.p.A.","startDate":"2014-10-01","conditions":"Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT00042406","phase":"PHASE2, PHASE3","title":"Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker","status":"TERMINATED","sponsor":"Genmab","startDate":"2002-03-04","conditions":"Rheumatoid Arthritis","enrollment":83},{"nctId":"NCT02772965","phase":"PHASE3","title":"Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2016-10","conditions":"Pediatric Crohn's Disease","enrollment":306},{"nctId":"NCT04247815","phase":"PHASE2","title":"Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA","status":"COMPLETED","sponsor":"Aclaris Therapeutics, Inc.","startDate":"2020-03-16","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03813199","phase":"PHASE2","title":"Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abivax S.A.","startDate":"2019-07-04","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT04095858","phase":"PHASE3","title":"Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)","status":"TERMINATED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2021-01-05","conditions":"Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT03589833","phase":"PHASE4","title":"Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-14","conditions":"Arthritis, Rheumatoid","enrollment":504},{"nctId":"NCT04227366","phase":"PHASE3","title":"Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2019-11-19","conditions":"Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT03522415","phase":"PHASE3","title":"Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2018-05-28","conditions":"Moderately to Severely Active Rheumatoid Arthritis","enrollment":275},{"nctId":"NCT05363917","phase":"PHASE2","title":"Natrunix Versus Methotrexate in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"XBiotech, Inc.","startDate":"2022-06-15","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02043587","phase":"PHASE2","title":"Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2014-01","conditions":"Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma","enrollment":31},{"nctId":"NCT03148860","phase":"PHASE3","title":"Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2016-12-15","conditions":"Psoriatic Arthritis","enrollment":186},{"nctId":"NCT02079948","phase":"PHASE2","title":"Inflammation Control For Elders: ICE Study","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2014-02","conditions":"Inflammation, Aging","enrollment":""},{"nctId":"NCT05117593","phase":"PHASE1","title":"Investigate the Safety, Tolerability and Pharmacokinetics of FBL-MTX","status":"COMPLETED","sponsor":"SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd","startDate":"2021-06-28","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT02366091","phase":"PHASE2","title":"Inflammation and Coronary Endothelial Function","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-01","conditions":"Coronary Artery Disease","enrollment":111},{"nctId":"NCT03163966","phase":"PHASE2","title":"A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Rottapharm Biotech","startDate":"2017-10-05","conditions":"Rheumatoid Arthritis, DMARD-naive and Early Disease Patients","enrollment":248},{"nctId":"NCT00299182","phase":"PHASE1, PHASE2","title":"Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-03","conditions":"Lymphoma","enrollment":50},{"nctId":"NCT01960855","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-10","conditions":"Rheumatoid Arthritis","enrollment":276},{"nctId":"NCT01651936","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-08-29","conditions":"Rheumatoid Arthritis","enrollment":56},{"nctId":"NCT02066389","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-03-26","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT01716039","phase":"PHASE2","title":"Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Alimentiv Inc.","startDate":"2013-06","conditions":"Ulcerative Colitis","enrollment":22},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02886728","phase":"PHASE3","title":"Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-08","conditions":"Rheumatoid Arthritis","enrollment":1252},{"nctId":"NCT02873936","phase":"PHASE3","title":"Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-07-27","conditions":"Rheumatoid Arthritis","enrollment":449},{"nctId":"NCT03275025","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2017-04-01","conditions":"Rheumatoid Arthritis","enrollment":116},{"nctId":"NCT00489203","phase":"PHASE2","title":"Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2007-04","conditions":"Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission","enrollment":140},{"nctId":"NCT04610567","phase":"PHASE1, PHASE2","title":"Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-27","conditions":"Coronavirus, Inflammation, Covid19","enrollment":100},{"nctId":"NCT02504671","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-23","conditions":"Arthritis, Rheumatoid","enrollment":222},{"nctId":"NCT02799472","phase":"PHASE2","title":"Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-15","conditions":"Arthritis, Rheumatoid","enrollment":39},{"nctId":"NCT04312815","phase":"PHASE3","title":"A Study Assessing the Efficacy and Safety of SM03 in Patients With Active Rheumatoid Arthritis Receiving MTX","status":"UNKNOWN","sponsor":"SinoMab BioScience Ltd","startDate":"2017-12-28","conditions":"Rheumatoid Arthritis(RA)","enrollment":510},{"nctId":"NCT02647762","phase":"PHASE3","title":"CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Can-Fite BioPharma","startDate":"2017-10-30","conditions":"Rheumatoid Arthritis","enrollment":244},{"nctId":"NCT01894516","phase":"PHASE2","title":"Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)","status":"COMPLETED","sponsor":"Galapagos NV","startDate":"2013-10-08","conditions":"Rheumatoid Arthritis","enrollment":287},{"nctId":"NCT03058900","phase":"NA","title":"Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2017-05-16","conditions":"Psoriatic Arthritis","enrollment":31},{"nctId":"NCT00406419","phase":"PHASE3","title":"A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2006-12-27","conditions":"Rheumatoid Arthritis","enrollment":1015},{"nctId":"NCT02065713","phase":"PHASE3","title":"Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Instituto de Medicina Molecular João Lobo Antunes","startDate":"2014-08","conditions":"Psoriatic Arthritis","enrollment":44},{"nctId":"NCT04616872","phase":"PHASE2, PHASE3","title":"Treatment of Patients With Atherosclerotic Disease With Methotrexate-associated to LDL Like Nanoparticles","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-10-10","conditions":"Atherosclerosis, Coronary Artery Disease, Inflammation","enrollment":40},{"nctId":"NCT00485589","phase":"PHASE3","title":"A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2007-06-11","conditions":"Rheumatoid Arthritis","enrollment":613},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT01594333","phase":"PHASE3","title":"Cardiovascular Inflammation Reduction Trial","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2013-04","conditions":"Cardiovascular Disease","enrollment":4786},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT02000336","phase":"PHASE3","title":"Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Prof. Dr. rer. nat. H.J. Trampisch","startDate":"2014-01","conditions":"Progression of Rheumatoid Arthritis","enrollment":395},{"nctId":"NCT04326894","phase":"PHASE4","title":"Methorexate and Knee Osteoarthritis","status":"COMPLETED","sponsor":"University of Alexandria","startDate":"2011-12","conditions":"Pain Reduction, Physical Function Improvement","enrollment":128},{"nctId":"NCT02831855","phase":"PHASE4","title":"Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-09-01","conditions":"Rheumatoid Arthritis","enrollment":694},{"nctId":"NCT04154852","phase":"PHASE2","title":"ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-06","conditions":"Oligoarthritis","enrollment":22},{"nctId":"NCT01303874","phase":"PHASE4","title":"Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis","enrollment":112},{"nctId":"NCT01308255","phase":"PHASE4","title":"Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":112},{"nctId":"NCT01711359","phase":"PHASE3","title":"A Study in Participants With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-11","conditions":"Rheumatoid Arthritis","enrollment":588},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT02265705","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT02467504","phase":"PHASE2","title":"Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Peking University People's Hospital","startDate":"2015-07-01","conditions":"Rheumatoid Arthritis","enrollment":47},{"nctId":"NCT02309359","phase":"PHASE2","title":"A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-01","conditions":"Rheumatoid Arthritis","enrollment":345},{"nctId":"NCT03217734","phase":"PHASE2, PHASE3","title":"MAP Study: Methotrexate and Adalimumab in Psoriasis","status":"COMPLETED","sponsor":"Jeffrey J Crowley MD","startDate":"2017-04-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT02882087","phase":"PHASE2","title":"A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis","status":"TERMINATED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-10","conditions":"Moderate and Severe Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02387762","phase":"PHASE2","title":"ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2015-04","conditions":"Rheumatoid Arthritis","enrollment":31},{"nctId":"NCT01569152","phase":"PHASE2","title":"Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-22","conditions":"Rheumatoid Arthritis (RA)","enrollment":82},{"nctId":"NCT01679951","phase":"PHASE2","title":"A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-10-31","conditions":"Rheumatoid Arthritis","enrollment":272},{"nctId":"NCT02312219","phase":"","title":"PET/CT Imaging Companion Study To ACTG A5314","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-11","conditions":"HIV, Inflammation, Atherosclerosis","enrollment":35},{"nctId":"NCT00689728","phase":"PHASE2","title":"A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT01871649","phase":"PHASE3","title":"Initial Treatment With Golimumab in Early PsA","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-08","conditions":"Psoriatic Arthritis","enrollment":51}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MTX"],"phase":"phase_3","status":"active","brandName":"Placebo + Methotrexate (MTX)","genericName":"Placebo + Methotrexate (MTX)","companyName":"UCB Pharma","companyId":"ucb","modality":"Biologic","firstApprovalDate":"","aiSummary":"Methotrexate inhibits dihydrofolate reductase to suppress DNA synthesis and reduce inflammatory immune cell proliferation. Used for Rheumatoid arthritis, Other autoimmune/inflammatory conditions (specific indication dependent on trial protocol).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}